Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonucleotide reductase subunit 1 (RRM1) is the large subunit of ribonucleotide reductase, a key enzyme that catalyzes the reduction of ribonucleoside diphosphates to deoxyribonucleoside diphosphates, providing the essential precursors for DNA synthesis and repair[1][4]. RRM1, together with the small subunit (RRM2 or RRM2B in humans), forms the active enzyme complex and is regulated allosterically to balance the relative concentrations of deoxyribonucleotides required for DNA replication and cell division[1]. Ribonucleotide reductase activity is vital for cell proliferation, and its inhibition forms the basis of several anti-cancer and antiviral therapies. Abnormal expression or dysregulation of RRM1 is associated with altered sensitivity to chemotherapeutics and with various malignancies, making it both a therapeutic target and a predictive biomarker[1][4].
Inhibition of deoxyribonucleotide synthesis (prevents DNA synthesis and repair by limiting the supply of deoxynucleotides)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleotide reductase subunit 1 (RRM1).